secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001641172-25-014648
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 shows dose-dependent reversal of Wilson's disease symptoms in animal model
--------------------------------------------------------------------------------

- Up to 4-5x reduction in episodic tremor events; normalization of swim and exploratory behavior.
- Approximately 50% reduction in copper accumulation in dry liver tissue.
- ALT, AST, bilirubin restored to normal levels, indicating protection of liver function.
- Significant improvement in liver and kidney histopathology scores to near-normal.
- IND submission planned by year-end; human clinical trials targeted for H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225014648/0001641172-25-014648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225014648/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer